New hope for advanced breast cancer: drug combo targets resistant tumors
NCT ID NCT06764186
First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times
Summary
This study tests a combination of two drugs, capivasertib and fulvestrant, in 101 people with a specific type of advanced breast cancer (HR+/HER2-) that has stopped responding to hormone therapy and a CDK4/6 inhibitor. The goal is to see how long it takes before the next cancer treatment is needed, while also checking safety. Participants must have a specific genetic change (PIK3CA/AKT1/PTEN) in their tumor.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HR+/HER2- ADVANCED BREAST CANCER WITH PIK3CA/AKT1/PTEN ALTERATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Alicante, 03010, Spain
-
Research Site
Barcelona, 08003, Spain
-
Research Site
Barcelona, 08035, Spain
-
Research Site
Barcelona, 08036, Spain
-
Research Site
Bilbao (Vizcaya), 48013, Spain
-
Research Site
Córdoba, 14004, Spain
-
Research Site
Donostia / San Sebastian, 20014, Spain
-
Research Site
El Palmar, 30120, Spain
-
Research Site
Girona, 17007, Spain
-
Research Site
Madrid, 28041, Spain
-
Research Site
Oviedo, 33011, Spain
-
Research Site
Palma deMallorca, 07010, Spain
-
Research Site
Salamanca, 37007, Spain
-
Research Site
Santander, 39008, Spain
-
Research Site
Seville, 41073, Spain
-
Research Site
Valencia, 46026, Spain
-
Research Site
Zaragoza, 50009, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug YL202 targets Hard-to-Treat breast cancers
- Simple gloves and socks may shield breast cancer patients from chemo nerve pain
- New hope for advanced breast cancer: YL202 takes on standard treatments in major trial
- New drug shows promise in slowing advanced breast cancer with ESR1 mutation
- New hope for Drug-Resistant breast cancer: phase 3 trial launches
- New hope for advanced breast cancer: drug combo targets resistant tumors